<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319628</url>
  </required_header>
  <id_info>
    <org_study_id>XMT-1536-1</org_study_id>
    <nct_id>NCT03319628</nct_id>
  </id_info>
  <brief_title>First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b</brief_title>
  <official_title>A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mersana Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IQVIA Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mersana Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536&#xD;
      (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks.&#xD;
      Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients&#xD;
      with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma&#xD;
      subtype) are being enrolled in the expansion segment of this study. Patients with&#xD;
      platinum-resistant, high-grade serous ovarian cancer are being enrolled in the UPLIFT segment&#xD;
      of this study. In addition to safety assessments, the pharmacokinetics of the drug will be&#xD;
      assessed along with ADC activity. A QTc sub-study has been added for the UPLIFT cohort for a&#xD;
      sub-set of sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center study of XMT-1536 (upifitamab rilsodotin) in patients with tumors&#xD;
      likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and&#xD;
      non-small cell lung cancer, adenocarcinoma subtype. XMT-1536 (upifitamab rilsodotin) will be&#xD;
      administered as an intravenous infusion once every four weeks. The study consists of three&#xD;
      segments: dose escalation (DES), dose expansion (EXP), and the pivotal cohort (UPLIFT). The&#xD;
      DES segment studied small groups of patients who received increased doses. A Safety Review&#xD;
      Committee was established to review the data from each dose level before moving to the next&#xD;
      higher dose. The dose escalation cohort has ended and is no longer enrolling patients.&#xD;
      Enrollment into the EXP segment consists of 2 parallel cohorts of patients to confirm the&#xD;
      dose that has been identified in DES and estimate the objective response rate in each patient&#xD;
      population. The EXP cohort is no longer enrolling patients. Enrollment into the pivotal&#xD;
      cohort (UPLIFT) includes patients with platinum-resistant ovarian cancer. All adverse events&#xD;
      will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria&#xD;
      version (CTCAE v5.0). Throughout the study, pharmacokinetics will be measured using&#xD;
      proprietary assays developed by Mersana. Anti-cancer activity will be measured via RECIST.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, dose escalation to reach MTD. The MTD will be confirmed in parallel cohorts: patients with platinum-resistant ovarian cancer; patients with non-squamous NSCLC, adenocarcinoma subtype</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DES: Maximum tolerated dose or recommended Phase 2 dose</measure>
    <time_frame>Up to 36 weeks, from the date of first dose until unacceptable side effects or a dose-limiting toxicity is met</time_frame>
    <description>Evaluate adverse events and concomitant medication use after XMT-1536 (upifitamab rilsodotin) doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DES and EXP: Safety and Tolerability</measure>
    <time_frame>First dose up until 30 days after study termination</time_frame>
    <description>Evaluate incidence and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EXP: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin)</measure>
    <time_frame>Every 6 weeks for up to 36 weeks</time_frame>
    <description>Monitor tumor size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UPLIFT: Investigator-assessed objective response rate (ORR) of XMT-1536 (upifitamab rilsodotin) in the ITT-Higher NaPi2b population</measure>
    <time_frame>Every 8 weeks until disease progression or up to 24 months</time_frame>
    <description>Confirmed ORR is defined as the proportion of patients who have achieved a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 after the initiation of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTc Sub-study: Evaluation of the concentration response analysis of XMT-1536 versus the change in QTcF values</measure>
    <time_frame>60 minutes prior to first dose, up to 26 hours after Cycle 3 dose</time_frame>
    <description>&quot;The concentration-QTcf change from baseline deltaQTcF analysis and analysis of central tendency for deltaQTcF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DES and EXP: Time of maximum observed concentration of XMT-1536 (upifitamab rilsodotin)</measure>
    <time_frame>Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses</time_frame>
    <description>Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DES and EXP: Maximum concentration of XMT-1536 (upifitamab rilsodotin)</measure>
    <time_frame>Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses</time_frame>
    <description>Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DES and EXP: Area under the concentration curve of the last measurable concentration of XMT-1536 (upifitamab rilsodotin)</measure>
    <time_frame>Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses</time_frame>
    <description>Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DES: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin)</measure>
    <time_frame>Every 6 weeks for up to 36 weeks</time_frame>
    <description>Monitor tumor size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DES and EXP: Anti-drug antibody and neutralizing antibody</measure>
    <time_frame>Every 6 weeks for up to 36 weeks</time_frame>
    <description>Analyze blood for antibodies to XMT-1536 (upifitamab rilsodotin) and neutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPLIFT: Investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) regardless of NaPi2b expression</measure>
    <time_frame>Every 8 weeks until disease progression or up to 24 months</time_frame>
    <description>Assess the investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) regardless of NaPi2b expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPLIFT: Objective response rate by independent radiology review (IRR) for patients with higher NaPi2b and overall</measure>
    <time_frame>Every 8 weeks until disease progression or up to 24 months</time_frame>
    <description>Assess the objective response rate by IRR for patients with higher NaPi2b and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPLIFT: Duration of objective response (DOR)</measure>
    <time_frame>4 weeks after first response and every 8 weeks until disease progression or up to 24 months</time_frame>
    <description>Assess the duration of objective response (DOR) in patients who achieve a response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPLIFT: Incidence and severity of adverse events</measure>
    <time_frame>First dose up until 60 days after study termination</time_frame>
    <description>Evaluate incidence and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc Sub-Study: Evaluation of the effect of XMT-1536 on QTcF in patients with platinum-resistant HGSOC by timepoint analysis</measure>
    <time_frame>60 minutes prior to first dose, up to 26 hours after Cycle 3 dose</time_frame>
    <description>Con.-QTc evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc Sub-Study: Evaluation of the effect of XMT-1536 on the PR-interval (PR), QRS duration (QRS), Heart Rate (HR), and ECG morphology</measure>
    <time_frame>60 minutes prior to first dose, up to 26 hours after Cycle 3 dose</time_frame>
    <description>Con.-QTc evaluation</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>Platinum Resistant Ovarian Cancer</condition>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XMT-1536 (upifitamab rilsodotin) treatment is administered in groups of patients who will receive doses that increase over time.&#xD;
This cohort is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion - Ovarian Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.&#xD;
Patients with ovarian cancer will enroll until sites approve UPLIFT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion - NSCLC adenocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.&#xD;
This cohort is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pivotal Cohort (UPLIFT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with platinum-resistant ovarian cancer will receive XMT-1536 (upifitamab rilsodotin) to further confirm the efficacy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QTc Sub-Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>upifitamab rilsodotin</intervention_name>
    <description>XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.&#xD;
For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion - NSCLC adenocarcinoma</arm_group_label>
    <arm_group_label>Dose Expansion - Ovarian Cancer</arm_group_label>
    <arm_group_label>Pivotal Cohort (UPLIFT)</arm_group_label>
    <arm_group_label>QTc Sub-Study</arm_group_label>
    <other_name>XMT-1536</other_name>
    <other_name>UpRi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria (for Dose Escalation, Expansion, and UPLIFT):&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Measurable disease as per RECIST, version 1.1&#xD;
&#xD;
          -  Resolution of all acute toxic effects of prior therapy or surgical procedures to&#xD;
             ≤Grade 1 (except alopecia, stable immune-related toxicity such as hypothyroidism on&#xD;
             hormone replacement, adrenal insufficiency on ≤10 mg daily prednisone [or equivalent],&#xD;
             chronic Grade 2 peripheral sensory neuropathy after prior taxane therapy).&#xD;
&#xD;
          -  Cardiac left ventricular ejection fraction (LVEF) ≥50% or ≥ the institution's lower&#xD;
             limit of normal by either Echo or MUGA scan&#xD;
&#xD;
          -  Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1500 cells/mm3&#xD;
&#xD;
               2. Platelet count ≥100,000/mm3&#xD;
&#xD;
               3. Hemoglobin ≥9 g/dL&#xD;
&#xD;
               4. In patients not on anticoagulation therapy: INR, activated partial thromboplastin&#xD;
                  time (aPTT), and prothrombin time (PT) all within 1.2 times the institution's&#xD;
                  upper limit of normal (ULN). Patients on anticoagulation therapy are allowed if&#xD;
                  their relevant laboratory values are within the therapeutic window.&#xD;
&#xD;
               5. Estimated glomerular filtration rate (GFR) ≥45 mL/min&#xD;
&#xD;
               6. Total bilirubin ≤ULN&#xD;
&#xD;
               7. g. Patients with asymptomatic elevations in unconjugated bilirubin due to Gilbert&#xD;
                  syndrome or stable chronic hemolytic anemia (e.g., hereditary spherocytosis,&#xD;
                  sickle cell disease, thalassemia intermedia) may be eligible after discussion&#xD;
                  with the Sponsor Medical Monitor.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT)&#xD;
             ≤1.5 times the institutional ULN.&#xD;
&#xD;
          -  Albumin ≥3.0 g/dL&#xD;
&#xD;
          -  Able to provide informed consent.&#xD;
&#xD;
        General Exclusion Criteria (for Dose Escalation, Expansion, and UPLIFT) :&#xD;
&#xD;
          -  Major surgery within 28 days of starting study treatment, systemic anti-cancer therapy&#xD;
             within the lesser of 28 days or 5 half-lives of the prior therapy before starting&#xD;
             study treatment, or recent radiation therapy with unresolved toxicity or within a time&#xD;
             window of potential toxicity.&#xD;
&#xD;
          -  Patients with untreated CNS metastases (including new and progressive brain&#xD;
             metastases), history of leptomeningeal metastasis or carcinomatous meningitis.&#xD;
&#xD;
          -  Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.&#xD;
&#xD;
          -  Prior history of liver disease such as liver cirrhosis, hepatic fibrosis&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease (e.g., clinically significant&#xD;
             cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could&#xD;
             interfere with per-protocol evaluations.&#xD;
&#xD;
          -  Current use of either constant or intermittent supplementary oxygen therapy.&#xD;
&#xD;
          -  History of suspected pneumonitis or interstitial lung disease.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  History of other malignancy within the last 2 years, except for appropriately treated&#xD;
             carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with&#xD;
             a similar expected curative outcome.&#xD;
&#xD;
          -  Active corneal disease, or history of corneal disease within 12 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Use of strong CYP450 inhibitors&#xD;
&#xD;
          -  Oxygen saturation on room air &lt;93%&#xD;
&#xD;
        Ovarian Cancer Inclusion Criteria for UPLIFT:&#xD;
&#xD;
          -  Histological diagnosis of high grade serous ovarian cancer, which includes fallopian&#xD;
             tube, or primary peritoneal cancer, that is metastatic or recurrent.&#xD;
&#xD;
          -  Platinum-resistant disease&#xD;
&#xD;
               1. Patients who have only had 1 line of platinum-based therapy must have received at&#xD;
                  least 4 cycles of platinum, must have had a response [complete response/remission&#xD;
                  (CR) or partial response/remission (PR)], and then progressed between 3 months&#xD;
                  and ≤ 6 months after the date of the last dose of platinum&#xD;
&#xD;
               2. Patients who have received 2 to 4 lines of prior therapy must have received at&#xD;
                  least 4 cycles of platinum and then progressed within 6 months after the date of&#xD;
                  the last dose of platinum&#xD;
&#xD;
          -  One to 4 prior lines of systemic therapy for ovarian cancer&#xD;
&#xD;
             a. Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines&#xD;
             of therapy&#xD;
&#xD;
          -  Patients must be willing to provide an archival tumor tissue block or slides or if not&#xD;
             available, undergo procedure to obtain a new tumor biopsy using a low-risk, medically&#xD;
             routine procedure&#xD;
&#xD;
        Ovarian Cancer Exclusion Criteria for UPLIFT:&#xD;
&#xD;
          -  Low-grade, clear cell, endometrioid, mucinous, carcinosarcoma, germ-cell, mixed&#xD;
             histology, or stromal tumors&#xD;
&#xD;
          -  Prior treatment with mirvetuximab soravtansine or another ADC containing an&#xD;
             antitubulin payload&#xD;
&#xD;
          -  Primary platinum-resistant disease, defined by a lack of response or by progression&#xD;
             within 3 months after completing front-line, platinum-containing therapy.&#xD;
&#xD;
          -  Participation in DES or EXP segments of this study&#xD;
&#xD;
        Ovarian Cancer Inclusion Criteria for QTc sub-study:&#xD;
&#xD;
        Note: patients must meet all UPLIFT cohort inclusion criteria in order to participate in&#xD;
        the QTc sub-study&#xD;
&#xD;
        • Study patient has agreed to remain in the clinic for the additional QTc related study&#xD;
        activities on the Day 1 of Cycle 1 and Cycle 3.&#xD;
&#xD;
        Ovarian Cancer Exclusion Criteria for QTc sub-study:&#xD;
&#xD;
          -  Use of strong CYP3A4 inducers.&#xD;
&#xD;
          -  Uncontrolled cardiac arrhythmias, for example, atrial fibrillation with a ventricular&#xD;
             response at rest &gt; 100 beats per minute. left bundle branch block (LBBB)&#xD;
&#xD;
          -  Known abnormality of any cardiac valve (either stenosis or regurgitation) that is&#xD;
             greater than moderate in severity.&#xD;
&#xD;
          -  Subjects not in sinus rhythm at screening with HR &gt;45- &lt;100&#xD;
&#xD;
          -  Any ECG abnormality that can interfere with the measurement of the QT interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Burger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mersana Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Azniv Shahverdyan</last_name>
    <phone>617-715-8211</phone>
    <email>ashahverdyan@mersana.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Barrett</last_name>
    <phone>617-498-0020</phone>
    <email>jbarrett@mersana.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adelyn Gillon</last_name>
      <phone>205-975-5958</phone>
      <email>agillon@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Arend, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Ambriz</last_name>
      <phone>520-546-2823</phone>
    </contact>
    <investigator>
      <last_name>Joseph Buscema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Maffei</last_name>
      <email>maria.maffei@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Bobbie Rimel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jill Tseng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Keitkamp</last_name>
      <email>hheitkam@ridleytreecc.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Kendle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bradley Corr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curi Ramsey</last_name>
      <phone>303-930-5554</phone>
    </contact>
    <investigator>
      <last_name>Robert Jotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lynn</last_name>
      <phone>352-265-9726</phone>
      <email>Melissa.Lynn@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Frederic Kaye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chinar Singh</last_name>
      <phone>305-243-8237</phone>
      <email>cxs1102@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Marilyn Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Castellano Fornelli</last_name>
      <phone>813-745-2970</phone>
      <email>Marianna.CastellanoFornelli@moffit.org</email>
    </contact>
    <investigator>
      <last_name>Andreas Saltos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Nelson</last_name>
      <phone>404-778-0869</phone>
      <email>joy.nelson@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Taofek Owonikoko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa James</last_name>
      <email>mejames@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Sharad Ghamande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology and Hematology</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brima Cherif</last_name>
      <phone>240-826-2118</phone>
    </contact>
    <investigator>
      <last_name>John Walmark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sara Bouberhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Insititute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Polin</last_name>
      <phone>617-632-2451</phone>
    </contact>
    <investigator>
      <last_name>Ursula Matulonis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corrine Zarwan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Schneider</last_name>
      <phone>313-576-9749</phone>
    </contact>
    <investigator>
      <last_name>Ira Winer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Gardner</last_name>
      <phone>313-916-7450</phone>
    </contact>
    <investigator>
      <last_name>Ding Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Bardram</last_name>
      <phone>248-957-8340</phone>
    </contact>
    <investigator>
      <last_name>Mohammed Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START - Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Estkowski</last_name>
      <phone>616-954-5551</phone>
    </contact>
    <investigator>
      <last_name>Nehal Lakhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrisann Winslow</last_name>
      <phone>314-747-1749</phone>
    </contact>
    <investigator>
      <last_name>Premal Thaker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Justin Bottsford-Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kacey Anthone</last_name>
      <email>Kacey.Anthone@nmhs.org</email>
    </contact>
    <investigator>
      <last_name>Brent Tierney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Women's Oncology- Optimum Clinical Research Group</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Finkelstein</last_name>
    </contact>
    <investigator>
      <last_name>Karen Finkelstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Care Associates, LLC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolina Suriano</last_name>
      <phone>518-458-1390</phone>
    </contact>
    <investigator>
      <last_name>Joyce Barlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhavana Pothuri</last_name>
    </contact>
    <investigator>
      <last_name>Bhavana Pothuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deborah Doroshow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Olson</last_name>
      <phone>980-442-2316</phone>
    </contact>
    <investigator>
      <last_name>Wendel Naumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Fuhman</last_name>
    </contact>
    <contact_backup>
      <email>fuhrmaba@ucmail.uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Davendra Sohal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anyssa Armstead</last_name>
      <phone>614-688-8846</phone>
      <email>Annyssa.Armstead@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>John Hays, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kattering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Keeton</last_name>
      <email>Kelly.Keeton@ketteringhealth.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Reid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Centre-University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phase 1 Research Nurses</last_name>
      <email>Phase1ResearchNurses@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Debra Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Kanoff</last_name>
      <phone>541-221-1731</phone>
    </contact>
    <investigator>
      <last_name>Charles Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Edelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Platts</last_name>
      <phone>412-623-5950</phone>
      <email>plattsa2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Burns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-330-6151</phone>
      <email>clinicaltrials@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Krivak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Locke</last_name>
      <email>ELocke@Wihri.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Lokich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Transnational Oncology-Greenville Hospital System University Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerry Hendricks</last_name>
      <phone>864-455-3294</phone>
      <email>Gerry.Hendricks@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Edenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Flier</last_name>
      <email>Natasha.Flier@avera.org</email>
    </contact>
    <investigator>
      <last_name>David Starks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37996</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>865-305-5622</phone>
    </contact>
    <investigator>
      <last_name>Larry Kilgore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Costin</last_name>
      <phone>615-340-1584</phone>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaelyn Kappeler</last_name>
      <phone>512-421-4234</phone>
      <email>Kaelyn.Kappeler@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jason Melear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Arellano</last_name>
      <email>monica.arellano@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Teneriello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Bowers</last_name>
      <email>shawnna.bowers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mark Messing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyleigh Clark</last_name>
      <phone>972-566-3093</phone>
    </contact>
    <contact_backup>
      <last_name>Keisha Riser</last_name>
      <phone>972-566-3066</phone>
    </contact_backup>
    <investigator>
      <last_name>Minal Barve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Matthews</last_name>
    </contact>
    <investigator>
      <last_name>Carolyn Matthews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nori Sullivan</last_name>
      <phone>817-413-1760</phone>
      <email>Nori.Sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Richey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Watkins</last_name>
      <email>penny.watkins@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauryn Tuckett</last_name>
      <phone>210-593-5242</phone>
    </contact>
    <investigator>
      <last_name>Kyriakos Papadopolous, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia De Leon</last_name>
      <phone>210-580-9521</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Tolcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Molnar</last_name>
      <phone>801-587-4701</phone>
    </contact>
    <investigator>
      <last_name>Theresa Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia- Emily Couric Clinical Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Bugden</last_name>
      <phone>434-243-7064</phone>
    </contact>
    <investigator>
      <last_name>Linda Duska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialist</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Hasan</last_name>
      <phone>703-208-9285</phone>
    </contact>
    <investigator>
      <last_name>Alex Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya Washington</last_name>
      <phone>804-628-2682</phone>
      <email>slwashington@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Randall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BlueRidge Cancer Care Physicians</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Wade</last_name>
      <phone>540-793-8303</phone>
      <email>Kelly.Wade@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Paul Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Gao</last_name>
    </contact>
    <investigator>
      <last_name>Bo Gao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Health - Olivia Newton John Cancer Center</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 (03) 9496 5000</phone>
      <email>Paul.MITCHELL@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Paul Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 (03) 8559 5000</phone>
      <email>Linda.Mileshkin@petermac.org</email>
    </contact>
    <investigator>
      <last_name>Linda Mileshkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 (02) 8514 0000</phone>
      <email>Steven.Kao@lh.org.au</email>
    </contact>
    <investigator>
      <last_name>Steven Kao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(250) 712-3996</phone>
    </contact>
    <investigator>
      <last_name>Sara Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - The Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong-Nam Nathalie Nguyen</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>23985</phone_ext>
    </contact>
    <investigator>
      <last_name>Lucy Gilbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Univ di Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Covadonga Vidal</last_name>
      <phone>+34 (91) 353 1920</phone>
      <phone_ext>7501</phone_ext>
    </contact>
    <investigator>
      <last_name>Martin Gozalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melina Martin</last_name>
      <phone>+34 (91) 727 7516</phone>
    </contact>
    <investigator>
      <last_name>Andres Redondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

